What is being reported
For suspected side effects being reported for medicines, the MHRA publishes this information in the form of interactive Drug Analysis Profiles (iDAPs) which can be accessed below.
The MHRA have begun implementing a new enhanced format of data visualisations. This enables us to provide improvements in format, accessibility and data protection whilst allowing access to more data than has been published previously. The initial phase of this development involves the provision of COVID-19 vaccine data with further plans to include all routine vaccination data and replace existing iDAPs for medicines in 2023.
COVID-19 Vaccine reports
The COVID-19 vaccine reports contain a complete listing of all suspected adverse reactions that have been reported to the MHRA via the Yellow Card scheme for all COVID-19 vaccines. This includes all reports received from healthcare professionals, members of the public, and pharmaceutical companies. The information in the reports is updated in line with our summary of Yellow Card reporting publication.
This information does not represent an overview of the potential side effects associated with the vaccines. A list of the recognised adverse effects of the COVID-19 vaccines is provided in the information for healthcare professionals and the recipient information here.
Conclusions on the safety and risks of the vaccines cannot be made on the data shown in the reports alone. Therefore, when reviewing the data within the reports it is important to do so in the context of the essential guidance at the bottom of the report to ensure that you do not misinterpret the data.
Please select from the links below to access the report for each vaccine.
COVID-19 Vaccine - brand unspecified or not in routine use in the UK
Information regarding suspected adverse reactions to other vaccines is not currently available via these reports but is available upon request.
interactive Drug Analysis Profiles (iDAPs)
Medicines are listed alphabetically by the name of the active ingredient, not by the brand name. To find the name of the active substance in your medicine, look at the patient information leaflet that was supplied with it. You can find patient information leaflets here.
Each iDAP contains a complete listing of all suspected adverse reactions that have been reported to the MHRA via the Yellow Card scheme. This includes all reports received from healthcare professionals, members of the public, and pharmaceutical companies.
iDAPs provided on this website are regularly updated. Please be aware, however, that if you have reported a suspected adverse drug reaction it may not immediately appear on this website. There is a time lag of around one month from receipt of a report to it appearing in the iDAP.
When reviewing the data within an iDAP it is important to do so in the context of the essential guidance at the bottom of the report to ensure that you do not misinterpret the data.
Questions & comments
During their development iDAPs have been extensively tested with a variety of stakeholders, nevertheless if you have any questions or comments about how they should be used/ interpreted or if the substance you are interested in is not currently available, please do not hesitate to contact us.